H. Arioka

发表

The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin.

N. Saijo, T. Terada, H. Yokote, 1998, Mutation research.

In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant

H. Kato, T. Ohira, N. Saijo, 2005, Journal of Cancer Research and Clinical Oncology.

Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo

N. Saijo, Y. Ohe, K. Nishio, 1997, Japanese journal of cancer research : Gann.

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion

K. Eguchi, N. Saijo, Y. Ohe, 1994, Japanese journal of cancer research : Gann.

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.

K. Eguchi, H. Arioka, Y. Sasaki, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CPT‐11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer

K. Eguchi, N. Saijo, Y. Ohe, 1994, Japanese journal of cancer research : Gann.

Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.

K. Eguchi, Y. Ohe, H. Arioka, 1994, Cancer research.

Efficient Sampling Strategies for Forecasting Pharmacokinetic Parameters of Irinotecan (CPT‐11): Implication for Area Under the Concentration‐Time Curve Monitoring

H. Ohmatsu, K. Eguchi, N. Saijo, 1995, Therapeutic drug monitoring.

Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells.

J. Usuda, N. Saijo, K. Nishio, 2001, Lung cancer.

Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.

N. Saijo, H. Yokote, K. Nishio, 1996, Anticancer research.

Variability in measuring the Ki-67 labeling index in patients with breast cancer.

H. Arioka, T. Chishima, Y. Kakuta, 2015, Clinical breast cancer.

Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer

Kimito Yamada, H. Iwata, Y. Fujiwara, 2017, Cancer science.

A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance

H. Iwata, Kenichi Inoue, H. Arioka, 2012, Breast Cancer.

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site

M. Ando, M. Yunokawa, K. Yonemori, 2008, British Journal of Cancer.

Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells

J. Usuda, N. Saijo, K. Nishio, 2002, Cancer Chemotherapy and Pharmacology.

Hypersensitivity of NIH3T3 cells transformed by H‐RAS gene to DNA‐topoisomerase‐I inhibitors

H. Kato, T. Ohira, N. Saijo, 1996, International journal of cancer.

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors

H. Arioka, H. Murakami, T. Tamura, 2010, Cancer Chemotherapy and Pharmacology.

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

H. Arioka, T. Kawabe, M. Omata, 2011, Cancer Chemotherapy and Pharmacology.

Improvement by eicosanoids in cancer cachexia induced by LLC-IL6 transplantation

H. Kato, N. Saijo, H. Arioka, 2005, Journal of Cancer Research and Clinical Oncology.

Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy

M. Imamura, H. Arioka, S. Horiguchi, 2018, Cancer Chemotherapy and Pharmacology.

A Topoisomerase II Inhibitor, NK109, Induces DNA Single‐ and Double‐strand Breaks and Apoptosis

N. Saijo, K. Nishio, H. Arioka, 1996, Japanese journal of cancer research : Gann.

A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia

H. Arioka, T. Nishikawa, M. Ichikawa, 2019, Internal medicine.

Effect of Glutathione Depletion on Cisplatin Resistance in Cancer Cells Transfected with the γ‐Glutamylcysteine Synthetase Gene

N. Saijo, H. Yokote, K. Nishio, 1997, Japanese journal of cancer research : Gann.

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

H. Iwata, N. Kondo, T. Shimoi, 2020, Breast Cancer.

In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice

T. Ohira, N. Saijo, K. Nishio, 2004, Cancer Chemotherapy and Pharmacology.

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

H. Ueno, H. Arioka, K. Koike, 2014, Investigational New Drugs.

Correlation of Gene‐specific Damage with Cisplatin between Human Adenocarcinoma Cells and Peripheral Blood Mononuclear Cells Analyzed by Polymerase Chain Reaction‐stop Assay

N. Saijo, H. Arioka, Y. Heike, 1995, Japanese journal of cancer research : Gann.

In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells

N. Saijo, K. Nishio, H. Arioka, 1997, Japanese journal of cancer research : Gann.

Induction of Apoptosis in Bronchial Eosinophils: Beneficial or Harmful?

K. Ohta, H. Arioka, N. Yamashita, 2000, International Archives of Allergy and Immunology.

Identification ofcis-Acting DNA Elements of the Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene

N. Saijo, K. Nishio, H. Arioka, 1997 .

In vivo Effects of Apoptosis in Asthma Examined by a Murine Model

K. Ohta, T. Horiuchi, H. Arioka, 2001, International Archives of Allergy and Immunology.

Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes

K. Eguchi, N. Saijo, Y. Ohe, 1996, Cancer Chemotherapy and Pharmacology.

Ectopic p16ink4 expression enhances CPT‐11‐induced apoptosis through increased delay in S‐phase progression in human non‐small‐cell‐lung‐cancer cells

J. Usuda, N. Saijo, K. Nishio, 2000 .

[Microtubules and antineoplastic drugs].

N. Saijo, H. Arioka, 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance.

N. Saijo, K. Nishio, H. Arioka, 1995, Biochemical and biophysical research communications.

A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin

H. Ohmatsu, K. Eguchi, N. Saijo, 1994, Japanese journal of cancer research : Gann.

G06 : A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

M. Kudo, N. Izumi, I. Sheen, 2015 .

p16INK4 Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors

J. Yokota, N. Saijo, H. Yokote, 1997, Japanese journal of cancer research : Gann.

A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.

M. Kudo, O. Matsui, S. Kaneko, 2013, European journal of cancer.

Breast cancer manifested by hematologic disorders.

I. Endo, T. Ishikawa, H. Arioka, 2012, Journal of thoracic disease.

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors

H. Arioka, H. Murakami, T. Tamura, 2010, Cancer Chemotherapy and Pharmacology.

Phase I Clinical Trial of Irinotecan ( CPT-11 ) , 7-Ethyl-1 O-[ 441-piperidino ) .1-piperidino ] carbonyloxy-camptothecin , and Cisplatin in Combination with Fixed Dose of Vindesine in Advanced Non-Small Cell Lung Cancer '

H. Ohmatsu, K. Eguchi, H. Arioka, 2006 .

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6

N. Saijo, Y. Ohe, K. Nishio, 2001, Japanese journal of cancer research : Gann.

Enhanced interaction between tubulin and microtubule‐associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel

N. Saijo, H. Arioka, H. Kurokawa, 1995, International journal of cancer.

Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.

I. Endo, T. Ishikawa, K. Tsugawa, 2019, Breast.

Enhancement of Cisplatin Sensitivity in High Mobility Group 2 cDNA‐transfected Human Lung Cancer Cells

Kazuya Fukuoka, N. Saijo, H. Yokote, 1999, Japanese journal of cancer research : Gann.

Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.

N. Saijo, H. Arioka, T. Ishida, 1996, Cancer research.

Cancer Chemotherapy-induced Oral and Gastrointestinal Mucosal Injury

H. Arioka, S. Akatsuka, 2008 .

A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane

H. Iwata, Y. Fujiwara, Kenichi Inoue, 2013, International Journal of Clinical Oncology.

Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy

H. Arioka, T. Miyaji, Takuhiro Yamaguchi, 2020, BMJ Open.

Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.

T. Yamanaka, M. Ando, M. Fukuda, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

M. Kudo, N. Izumi, I. Sheen, 2018, The lancet. Gastroenterology & hepatology.

Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL)

M. Kudo, O. Matsui, S. Kaneko, 2019, Medical Oncology.

Phorbol ester and okadaic acid-resistant cells: the crossroads of signal transduction and drug resistance.

N. Saijo, K. Nishio, H. Arioka, 1995, The American journal of medicine.

In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance

N. Saijo, K. Nishio, H. Arioka, 2005, Journal of Cancer Research and Clinical Oncology.

LBA63 Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial

H. Arioka, T. Miyaji, C. Katada, 2021, Annals of Oncology.

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

H. Ueno, H. Arioka, K. Koike, 2014, Investigational New Drugs.

Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy

M. Imamura, H. Arioka, S. Horiguchi, 2018, Cancer Chemotherapy and Pharmacology.

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site

M. Yunokawa, K. Yonemori, C. Shimizu, 2008, British Journal of Cancer.

Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography

H. Arioka, M. Fujiwara, T. Yanagihara, 2022, Medicine.